Blog
RSS FeedPosted by Michael Wonder on 06 Sep 2023
'Joint reimbursement of Opdivo, CDx platform marks milestone in gastric cancer but challenges remain'
6 September 2023 - Oncology experts celebrated the joint reimbursement of Opdivo together with its PD-L1 IHC 28-8 PharmDx companion ...
Posted by Michael Wonder on 21 Aug 2023
Patients get antsy amid protracted price bargaining for Spinraza, Evrysdi
21 August 2023 - Drug price negotiations for two spinal muscular atrophy drugs --Spinraza (nusinersen sodium) and Evrysdi (risdiplam) – ...
Posted by Michael Wonder on 31 Jul 2023
Bavencio gets coverage as first-line maintenance therapy for urothelial cancer
25 July 2023 - Merck’s anti-PD-L1 immuno-oncology drug Bavencio (avelumab) will get insurance coverage starting next month as first-line maintenance ...
Posted by Michael Wonder on 19 Jul 2023
Severe asthma treatment Cinqair passes drug review 6 years after approval
7 July 2023 - Teva Handok's severe asthma treatment Cinqair (reslizumab) crossed the threshold of the Drug Benefit Evaluation Committee ...
Posted by Michael Wonder on 11 Jul 2023
Pfizer's Cibinqo affordable at $77/month with reimbursement for severe atopic dermatitis
11 July 2023 - A Korean doctor expressed excitement that patients suffering from severe atopic dermatitis will be able to ...
Posted by Michael Wonder on 03 Jul 2023
‘Asthma care in Korea reminds me of Canada 8 years ago’
3 July 2023 - Korean-born expert in Canada stresses appropriate reimbursement for biological drugs. ...
Posted by Michael Wonder on 03 Jul 2023
Novartis’ Scemblix gets benefit to treat chronic myeloid leukaemia third or more times
30 June 2023 - Novartis' Scemblix (asciminib) will receive reimbursement for the third-line or more treatment of chronic myeloid leukaemia ...
Posted by Michael Wonder on 28 Jun 2023
Korea’s drug pricing policies for the second half of 2023
22 June 2023 - In the first half of 2023, the Ministry of Health and Welfare set up a public ...
Posted by Michael Wonder on 14 Jun 2023
Oral SMA drug Evrysdi passes reimbursement review
2 June 2023 - The nation’s health insurance review agency said Roche's Evrysdi (risdiplam), an oral treatment for spinal muscular ...
Posted by Michael Wonder on 14 Jun 2023
Brukinsa gets reimbursement to treat rare blood cancer patients
2 May 2023 - Beigene Korea said Monday that its Brukinsa 80 mg capsules (zanubrutinib) began to receive insurance benefits ...
Posted by Michael Wonder on 01 Jun 2023
BMS Korea wins insurance coverage for myelofibrosis drug Inrebic
1 June 2023 - BMS Korea has announced that Inrebic (fedratinib), its myelofibrosis drug, will now be covered by the ...
Posted by Michael Wonder on 20 May 2023
SMA patients protest inconsistent reimbursement standards for Spinraza
19 May 2023 - Spinal muscular atrophy patients taking Spinraza (nusinersen sodium) are protesting against the Health Insurance Review and ...
Posted by Michael Wonder on 17 May 2023
Astellas seeks to expand reimbursement for prostate cancer drug Xtandi
16 May 2023 - Astellas Pharma has set about to rectify the reimbursement track for Xtandi (enzalutamide), its prostate cancer ...
Posted by Michael Wonder on 09 May 2023
Opdivo to get reimbursement soon as primary treatment of stomach cancer
9 May 2023 - Opdivo (nivolumab), an anti-PD-1 immunotherapy, will likely receive insurance benefits soon as the primary treatment of ...
Posted by Michael Wonder on 27 Apr 2023
Even drugs winning fast-track nods frustrate before reimbursement wall
27 April 2023 - Several targeted agents for lung cancer approved through fast-track review due to their innovativeness and urgency ...